New vaccine aims to train immune system against breast cancer stem cells
NCT ID NCT02157051
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a DNA vaccine called STEMVAC in 42 people with advanced HER2-negative breast cancer whose disease is stable or gone after standard treatment. The vaccine is designed to help the immune system recognize and attack cancer stem cells, which are often resistant to chemotherapy. The main goals are to check safety and see if the vaccine boosts the body's immune response against the cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-NEGATIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Fasting during chemo: a new way to boost treatment?
- Can a smart drug cross the Blood-Brain barrier to attack breast cancer metastases?
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- Can radiation replace surgery for cancer spread to lymph nodes?
- Engineered immune cells join chemo and antibody to attack Hard-to-Treat breast cancer
- Could a common cholesterol drug boost breast cancer treatment?